...
首页> 外文期刊>Oncology letters >A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11
【24h】

A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11

机译:具有新的C634Y / D707E系列中的多个内分泌肿瘤型2A型大型杂交突变在RET外显子11

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The present study identified the clinical features of the largest multiple endocrine neoplasia type 2 (MEN2) A pedigree from China, with a novel double missense rearranged during transfection (RET) mutation (C634Y/D707E). To the best of our knowledge, the D707E mutation has not been identified to date: In the present study, a total of 101 family members who originated from a large pedigree (134 members in total) underwent RET mutation screening by next-generation sequencing and polymerase chain reaction (PCR) amplification, followed by direct bidirectional DNA sequencing. The clinical features of this pedigree were carefully reviewed retrospectively, and statistical analyses were conducted using SPSS software. A total of 33 (32.67%) carriers were identified to exhibit the C634Y/D707E RET germline mutation. The mean age of the patients with medullary thyroid carcinoma (MTC) identified by RET screening was 38.4 +/- 16.5 years (n=11; range, 14-65 years). Only 4 patients with pheochromocytoma with a median age of 37 years were identified. No. hyperparathyroidism was diagnosed. Persistent or recurrent disease developed in the patients of the present study who underwent inappropriate initial thyroid surgeries that were performed in previous decades (III10, III23, III24, III27 and IV46, as they had undergone two surgeries prior to the present study). A total of 66.70% (6/9) of patients, following thyroidectomy, continued to develop persistent or recurrent disease during the present screening study. In total, 3 patients succumbed to MTC or distant metastasis in the present study. The increase in carcinoembryonic antigen (CEA) levels correlated with the increase in basal serum calcitonin (Ct) levels according to Pearson correlation analysis in patients with MTC without surgery. Ct and CEA levels were also significantly correlated with tumor volumes. To the best of our knowledge, the present study is the first to identify a novel double RET missense mutation in the largest MEN2A pedigree from China. Additional in-depth study is necessary to elucidate the molecular mechanisms of the D707E mutation and its potential joint effects with the other C634Y mutation in the pedigree of the present study.
机译:本研究确定了来自中国的最大多个内分泌肿瘤型(MEN2)血统的临床特征,在转染(RET)突变(C634Y / D707E)期间重新调整了新的双重畸形。据我们所知,D707E突变尚未确定到目前为止:在本研究中,共有101名家庭成员,这些家庭成员来自大型血统(总共134名成员)通过下一代测序进行了RET突变筛选聚合酶链反应(PCR)扩增,其次是直接双向DNA测序。回顾性地仔细审查该谱系的临床特征,并使用SPSS软件进行统计分析。鉴定了总共33名(32.67%)的载体,表现出C634Y / D707E Ret种系突变。通过RET筛选鉴定的髓质甲状腺癌(MTC)的平均年龄为38.4 +/- 16.5岁(n = 11;范围,14-65岁)。只确定了4例嗜铬细胞瘤的患者,鉴定了37岁的中位数。不。诊断出甲状旁腺功能亢进症。本研究患者开发的持续性或复发性疾病,该研究患者在前几十年中进行了不恰当的甲状腺手术(III10,200i23,ii24,ii27和IV46,因为它们在本研究之前经过了两种手术)。在甲状腺切除术后,共有66.70%(6/9)患者继续在本筛查期间继续发育持续或复发性疾病。总共3名患者在本研究中屈服于MTC或远处转移。甲基丙烯醛抗原(CEA)水平的增加与MTC患者的Pearson相关分析没有手术的Pearson相关分析相关的基础血清降钙素CT和CEA水平也与肿瘤体积显着相关。据我们所知,本研究首先是识别来自中国最大的MEN2A血统的新型RET畸变突变。额外的深入研究是为了阐明D707E突变的分子机制及其与本研究血统中的其他C634Y突变的潜在关节效应。

著录项

  • 来源
    《Oncology letters》 |2017年第2期|共7页
  • 作者单位

    Capital Med Univ Beijing Tongren Hosp Dept Otolaryngol Head &

    Neck Surg 1 Dong Jiao Min Xiang;

    Capital Med Univ Beijing Tongren Hosp Dept Otolaryngol Head &

    Neck Surg 1 Dong Jiao Min Xiang;

    Capital Med Univ Beijing Tongren Hosp Dept Otolaryngol Head &

    Neck Surg 1 Dong Jiao Min Xiang;

    Capital Med Univ Beijing Tongren Hosp Dept Otolaryngol Head &

    Neck Surg 1 Dong Jiao Min Xiang;

    MyGenostics Inc Beijing 101318 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    MEN2A; medullary thyroid carcinoma; C634Y; D707E; double mutation;

    机译:MEN2A;髓质甲状腺癌;C634Y;D707E;双突变;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号